TScan Therapeutics Inc
TCRX
$7.29
Closing
▼-1.22%
1D
▲25.04%
YTD
Market cap
$366.70M
52 week high
$8.97
52 week low
$1.65
Volume
37,887
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$366.70M
Analysts' Rating
BUY
Price Target (Mean)
10.6
Total Analysts
5
P/E
Operating Margin
-636.69%
Beta
Revenue Growth (Annual)
33.47%
52 week high
$8.97
52 week low
$1.65
Div. Yield
%
EPS Annual Growth
-52.94
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. It is also advancing six solid tumor programs: TSC-204, entering Phase I development; TSC-200 and TSC-203, in IND-enabling activities; TSC-201, in lead optimization, and TSC-202 and TSC-205, in discovery.
